What Are the Early Signs of PML in Tysabri Patients?

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Occupational and Clinical Awareness

If you or a loved one is taking Tysabri, understanding the early signs of progressive multifocal leukoencephalopathy (PML) is critical. The medical community has long recognized the importance of monitoring patients for neurological changes during treatment. This page reviews the key clinical red flags and safety considerations outlined in Tysabri's prescribing information.

Understanding Tysabri and Its Association with PML

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its use is associated with a significantly increased risk of progressive multifocal leukoencephalopathy (PML), a severe and often fatal brain infection caused by the JC virus. The U.S. Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri, the agency's most stringent safety alert, to communicate this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML is a demyelinating disease of the central nervous system that occurs primarily in immunocompromised individuals. The condition results from reactivation of the JC polyomavirus, which destroys oligodendrocytes—the cells that produce myelin. Clinically, PML presents with a range of neurological deficits that evolve over weeks to months. Common symptoms include progressive weakness on one side of the body, cognitive decline, visual disturbances, and coordination problems. Diagnosis is typically confirmed through brain magnetic resonance imaging (MRI) showing characteristic white matter lesions, combined with detection of JC virus DNA in cerebrospinal fluid via polymerase chain reaction (PCR). In some cases, brain biopsy may be required. A retrospective national cohort study of 456 Italian PML patients observed between 1987 and 2024 found that 82.4% had a definite diagnosis, while 17.6% were diagnosed based on clinico-radiological criteria (https://pubmed.ncbi.nlm.nih.gov/40922664/). The study underscores the importance of early recognition, as PML can progress rapidly to severe disability or death.

Pharmacology and Reported Adverse Effects of Tysabri

Tysabri is a monoclonal antibody that binds to alpha-4 integrin, a cell adhesion molecule on the surface of lymphocytes. By blocking this interaction, Tysabri prevents immune cells from crossing the blood-brain barrier into the central nervous system. This mechanism reduces inflammatory activity in multiple sclerosis but also impairs immune surveillance against JC virus in the brain. The FDA Adverse Event Reporting System (FAERS) database lists fatigue, multiple sclerosis relapse, headache, gait disturbance, and fall as the most frequently reported adverse events among Tysabri users (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). However, the most serious adverse effect is PML. In clinical trials, PML occurred in three patients: two among 1,869 multiple sclerosis patients treated for a median of 120 weeks (both had also received interferon beta-1a), and one among 1,043 Crohn's disease patients after eight doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These cases highlight that PML can develop even with relatively short exposure.

Mechanistic Pathways Linking Tysabri to PML

The link between Tysabri and PML is well-established. By inhibiting lymphocyte trafficking into the brain, Tysabri reduces the immune system's ability to control JC virus replication. The virus, which is latent in most adults, can then reactivate and infect oligodendrocytes, leading to demyelination. Risk factors for PML include the presence of anti-JCV antibodies (indicating prior exposure to the virus), longer duration of Tysabri therapy, and prior use of immunosuppressant medications (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be weighed against the expected benefit when initiating or continuing treatment. The boxed warning advises healthcare professionals to monitor patients for any new signs or symptoms suggestive of PML and to withhold Tysabri immediately if such symptoms appear (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Adequacy of Warnings and Legal Considerations

The FDA has mandated a boxed warning for Tysabri since its reintroduction to the market in 2006, following a temporary withdrawal due to PML cases. The warning clearly states that Tysabri increases the risk of PML, an opportunistic viral infection that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Additionally, Tysabri is only available through a restricted distribution program called the TOUCH Prescribing Program, which aims to ensure that patients and prescribers are aware of the risks and that monitoring protocols are followed (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, questions may arise about whether the warnings are sufficient to prevent harm, particularly in patients who develop PML despite adherence to monitoring guidelines. For patients who develop PML after using Tysabri, legal considerations may include whether the manufacturer provided adequate warnings about the risk, whether the patient's specific risk factors were properly assessed, and whether monitoring was conducted appropriately. The boxed warning and TOUCH program represent regulatory efforts to mitigate risk, but individual cases may involve complex medical and legal questions. Patients and their families may seek legal counsel to explore options for compensation, especially if PML leads to severe disability or death. The timeline between Tysabri exposure and PML diagnosis is critical, as cases can occur after varying durations of treatment. In clinical trials, PML was observed after a median of 120 weeks in multiple sclerosis patients and after eight doses in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Post-marketing reports indicate that PML can occur earlier or later, depending on individual risk factors. The onset of PML symptoms can be insidious, and diagnosis may be delayed. The retrospective cohort study of Italian PML patients included cases diagnosed between 1987 and 2024, reflecting the long-standing nature of this disease (https://pubmed.ncbi.nlm.nih.gov/40922664/). For Tysabri-associated PML, the time from first dose to symptom onset varies. The boxed warning emphasizes that healthcare professionals should monitor patients for any new sign or symptom suggestive of PML and withhold Tysabri immediately if such symptoms appear (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Early detection and discontinuation of Tysabri may improve outcomes, but PML often leads to permanent neurological damage.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and how does it increase the risk of PML?

Tysabri (natalizumab) is a biologic therapy for multiple sclerosis and Crohn's disease. It works by blocking immune cells from entering the brain, which reduces inflammation but also impairs the brain's ability to fight the JC virus. This can lead to reactivation of the virus and cause progressive multifocal leukoencephalopathy (PML), a severe brain infection. The FDA has issued a boxed warning for this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the symptoms of PML and how is it diagnosed?

PML symptoms include progressive weakness, cognitive decline, vision problems, and coordination difficulties. Diagnosis is confirmed by brain MRI showing white matter lesions and detection of JC virus DNA in spinal fluid via PCR. A study of 456 Italian PML patients found that 82.4% had a definite diagnosis (https://pubmed.ncbi.nlm.nih.gov/40922664/). Early diagnosis is critical as PML can rapidly lead to severe disability or death.

What legal options are available for patients who developed PML after taking Tysabri?

Patients who develop PML may have legal claims if the manufacturer failed to provide adequate warnings or if monitoring was insufficient. The boxed warning and TOUCH program aim to mitigate risk, but individual cases may involve complex questions. Affected individuals should consult an attorney to explore compensation for medical expenses, disability, and other damages. The timeline from exposure to diagnosis is important, as PML can occur after varying durations of treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.